Abstract

Intervertebral disc degenerative disease (IDD) is the most common degenerative spine disease, which leads to chronic low back pain and symptoms in the lower extremities. In this study, we found that RORα, a member of the retinoid-related orphan receptor family, is significantly elevated in nucleus pulposus tissue in IDD patients. The elevation of RORα is associated with increased apoptosis of nucleus pulposus (NP) cells. Therefore, we applicated a well-established inverse agonist of RORα, SR3335, to investigate its role in regulating NP cell metabolism and apoptosis. To further investigate the mechanism that SR3335 regulates the pathogenesis of IDD in vitro, tumor necrosis factor alpha (TNF-α) stimulation was used in human NP cells to mimic the hostile environment that leads to degeneration. We found that SR3335 treatment reversed the trend of increased apoptosis in NP cells induced by TNF-α treatment. Next, TNF-α treatment upregulated the expression of type II collagen and aggrecan and downregulated MMP13 (matrix-degrading enzyme matrix metalloproteinase 13) and ADAMTS4 (a disintegrin and metalloproteinase with thrombospondin motifs 4). However, these effects were reversed after SR3335 treatment. Furthermore, we find that SR3335 mediated the effect in NP cells by regulating the YAP signaling pathway, especially by affecting the phosphorylation state of YAP. In conclusion, the reduction of matrix degradation enzymes and apoptosis upon SR3335 treatment suggests that SR3335 is a promising drug in reversing the deleterious microenvironment in IDD patients.

Highlights

  • Intervertebral disc degenerative disease (IDD) is one of the most common degenerative spine diseases that cause low back pain and subsequent chronic disability in the elderly [1]

  • We focus on the expression of RORα and its well-established inverse agonist SR3335 during nucleus pulposus (NP) cell degeneration

  • SR3335 treatment reversed the loss of matrix components in the puncture-induced rat IDD model

Read more

Summary

Introduction

Intervertebral disc degenerative disease (IDD) is one of the most common degenerative spine diseases that cause low back pain and subsequent chronic disability in the elderly [1]. Due to incomplete understanding of the etiology of IDD, the treatment can only provide pain relief during the exacerbation phase, and many patients will eventually have to receive surgery despite these pharmacological therapies [3]. The etiology of IDD remains unclear, some common features are suggested to be involved in the development of IDD, including biomechanics alternation, nucleus pulposus (NP) cell apoptosis, and loss of extracellular matrix (ECM) components [4]. During the progression of IDD, the excessive apoptosis of NP cells and production of proinflammatory cytokines and matrix metalloproteinase secretion consist of a pernicious cycle, which leads to the loss of ECM components such as type II collagen and aggrecan [5, 6]. We constructed an in vitro IDD model by treating NP cells with

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call